---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012293"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:57:21.352207+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M

## Summary
- Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.
- Cash $4.0M at June 30, 2024, up from $1.1M at Dec 31, 2023; operating cash burn $4.3M.
- Closed $4.0M private placement in June: 1.8M shares + warrants at $2.21/share.
- R&D expense down to $1.9M from $3.1M; G&A flat at $1.2M.
- Presented interim Phase 2 data for prexigebersen in AML at ASCO and EHA.

## SEC filing metadata
- accession: 0001558370-24-012293
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/0001558370-24-012293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/bpth-20240815x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012293
- JSON: https://secwatch.observer/filing/0001558370-24-012293.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.